https://www.miltenyibiomedicine.com/component---src-pages-cell-the…linical-programs-js-9772e7f9cf52900439d4.js

1"use strict";(self.webpackChunkgatsby_starter_default=self.webpackChunkgatsby_starter_default||[]).push([[3359],{283:function(e,t,l){t.A=l.p+"static/Patients_Dendric Cell-ac8925bb1b939be42ca7d6c530b3c063.svg"},417:function(e,t,l){t.A=l.p+"static/Patients_NK Cell-005c2f34de676960f78ec0f44c1361ae.svg"},1087:function(e,t,l){Object.defineProperty(t,"M",{enumerable:!0,get:function(){return a.AnchorLink}});var a=l(1547)},1547:function(e,t,l){Object.defineProperty(t,"__esModule",{value:!0}),t.AnchorLink=p;var a=s(l(6540)),n=l(4794),i=s(l(5556)),r=l(5642);function s(e){return e&&e.__esModule?e:{default:e}}function c(e,t){var l=Object.keys(e);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);t&&(a=a.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),l.push.apply(l,a)}return l}function o(e){for(var t=1;t<arguments.length;t++){var l=null!=arguments[t]?arguments[t]:{};t%2?c(Object(l),!0).forEach(function(t){m(e,t,l[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(l)):c(Object(l)).forEac

1h(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(l,t))})}return e}function m(e,t,l){return t in e?Object.defineProperty(e,t,{value:l,enumerable:!0,configurable:!0,writable:!0}):e[t]=l,e}function p(e){var t=e.to,l=e.title,i=e.children,s=e.className,c=e.stripHash,m=void 0!==c&&c,p=e.gatsbyLinkProps,u=void 0===p?{}:p,d=e.onAnchorLinkClick,g=m?r.handleStrippedLinkClick:r.handleLinkClick,h=o(o({},u),{},{to:m?(0,r.stripHashedLocation)(t):t,onClick:function(e){return g(t,e,d)}});return l&&(h.title=l),s&&(h.className=s),a.default.createElement(n.Link,h,i||l)}p.propTypes={to:i.default.string.isRequired,title:i.default.string,className:i.default.string,stripHash:i.default.bool,gatsbyLinkProps:i.default.object,onAnchorLinkClick:i.default.func,children:i.default.node}},5955:function(e,t,l){l.r(t),l.d(t,{default:function(){return y}});var a=l(6540),n=l(6353),i=l(7528),r=l(1768),s=l(8934),c=l(7712),o=l(7387);var m=({children:e,eventCategory:t,eventAction:l,eventLabel:n})=>{(0,a.useEffect)(()=>{},[]);const[i,r]=a.useState(!1);function s(e){e.preventDefault(),r(!1),document.body.className=document.body.className.replace("modal-is-open","")}return a.createElement("span",null,a.createElement("span",null,a.createElement("span",{className:"label label--info",onClick:function(e){e.preventDefault(),r(!0),document.body.classList.add("modal-is-open");var a={event:"interactiveBubble",eventCategory:t,eventAction:l,eventLabel:n};window.dataLayer.push(a)}})),a.createElement("div",{className:"modal "+(i?"is-open":"")},a.createElement("div",{className:"modal__close",onClick:s,onKeyDown:s,role:"button",tabIndex:0},a.createElement("span",null,"Close"),a.createElement("svg",{enableBackground:"new 0 0 100 100",id:"Layer_1",version:"1.1",viewBox:"0 0 100 100",xmlSpace:"preserve",xmlns:"http://www.w3.org/2000/svg",xmlnsXlink:"http://www.w3.org/1999/xlink"},a.createElement("polygon",{fill:"#010101",points:"77.6,21.1 49.6,49.2 21.5,21.1 19.6,23 47.6,51.1 19.6,79.2 21.5,81.1 49.6,53 77.6,81.1 79.6,79.2   51.5,51.1 79.6,23 "}))),e))},p=l(1087);function u(e){var t={event:"anchors",eventCategory:"Anchors",eventAction:e};window.dataLayer.push(t)}let d=function(e){function t(){return e.apply(this,arguments)||this}return(0,o.A)(t,e),t.prototype.render=function(){const{props:{index:e,item:t}}=this;return a.createElement("div",{className:"pipeline-item "+("pipeline-item--"+(e%2?"even":"odd")),style:{minHeight:200}},a.createElement("div",{className:"container"},a.createElement("div",{className:"row "},a.createElement("div",{className:"col-12 col-lg-1-7 pipeline-item__content"},a.createElement("p",{className:"pipeline-item__content-title"},a.createElement("span",{dangerouslySetInnerHTML:{__html:t.title}}),t.title_anchor&&a.createElement("span",{onClick:()=>u(t.title),onKeyDown:()=>u(t.title),role:"button",tabIndex:0},a.createElement(p.M,{className:"util-color-tertiary d-inline-block",to:"/research-pipeline#legend",title:"Info1"},a.createElement("sup",null,"1")))),t.no&&a.createElement("div",null,t.no.title," "),t.target.length>0&&a.createElement("p",{className:"util-color-black"},"Target: ",t.target.map((e,t)=>a.createElement("span",{key:t,className:"label_"},t>0?",":""," ",e)))),a.createElement("div",{className:"col-12 col-lg-6-7"},a.createElement("div",{className:"row pipeline-headline d-lg-none mb-4 mt-4"},a.createElement("div",{className:"col-3 "},"Preclinical"),a.createElement("div",{className:"col-3"},"Phase 1"),a.createElement("div",{className:"col-3 "},"Phase 2"),a.createElement("div",{className:"col-3 "},"Pivotal")),a.createElement("div",{className:"row d-lg-none"},a.createElement("div",{className:"col-3 pipeline-gutter pipeline-gutter--left pl-2"}),a.createElement("div",{className:"col-3 pipeline-gutter pipeline-gutter--left pl-2"}),a.createElement("div",{className:"col-3 pipeline-gutter pipeline-gutter--left pl-2"}),a.createElement("div",{className:"col-3 pipeline-gutter pipeline-gutter--left pl-2"})),a.createElement("div",{className:"row d-none d-lg-flex"},a.createElement("div",{className:"offset-lg-4 col-lg-2 pipeline-gutter pipeline-gutter--left"}),a.createElement("div",{className:"col-lg-2 pipeline-gutter pipeline-gutter--left"}),a.createElement("div",{className:"col-lg-2 pipeline-gutter pipeline-gutter--left"}),a.createElement("div",{className:"col-lg-2 pipeline-gutter pipeline-gutter--left"})),t.indication.map((e,t)=>a.createElement("div",{key:t,className:"pipeline-line mt-0"},a.createElement("div",{className:"row"},a.createElement("div",{className:"d-none d-lg-block col-4"},a.createElement("span",{dangerouslySetInnerHTML:{__html:e.title}}

1)),a.createElement("div",{className:"col-xs-12 col-lg-8"},a.createElement("p",{className:"d-lg-none font-weight-bold mb-0 mt-0"},"Indication"),a.createElement("div",{className:"mb-2 mt-0 d-lg-none",dangerouslySetInnerHTML:{__html:e.title}}),a.createElement("span",{className:"progress"},a.createElement("span",{className:` progress__active  progress__active--${e.progress}`},e.inline&&a.createElement("span",null,a.createElement("span",{className:"progress__link",dangerouslySetInnerHTML:{__html:e.inline.title}}),"",a.createElement(m,{eventCategory:"Research Pipeline i-bubble",eventAction:"Phase",eventLabel:e.inline.title},a.createElement("h3",{dangerouslySetInnerHTML:{__html:e.inline.title}}),a.createElement("p",{dangerouslySetInnerHTML:{__html:e.inline.text}}))),e.inline&&e.inline.hint&&a.createElement("span",{className:"progress__hint",dangerouslySetInnerHTML:{__html:e.inline.hint}})))))))))))},t}(a.Component);var g=d,h=JSON.parse('{"T":[{"title":"Zamto&shy;cabta&shy;gene <nobr>autoleucel<sup>1</sup></nobr>","target":["Tandem CD20-CD19"],"indication":[{"title":"r/r DLCBL 2L","progress":100,"inline":{"title":"NCT04844866","text":"A pivotal phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of zamtocabtagene autoleucel compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT04844866\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT04844866)</a>.","url":"https://clinicaltrials.gov/study/NCT04844866","hint":"Recruiting*"}},{"title":"r/r DLBCL 3L, CNSL, MCL, Richter Transformation","progress":100,"inline":{"title":"NCT04792489","text":"A prospective, single arm, open label, multi-center, phase II study of autologous T cells engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory DLBCL after receiving at least two lines of therapy.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT04792489\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NTC04792489)</a>.","url":"https://clinicaltrials.gov/study/NCT04792489","hint":"Recruiting"}},{"title":"r/r B-Cell Neoplasm – pediatric","progress":75,"inline":{"title":"NCT06508931","text":"A single-arm, multi-center, open-label phase II study designed to evaluate the efficacy of zamtocabtagene autoleucel therapy infusion in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT06508931\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT06508931)</a>.","url":"https://clinicaltrials.gov/study/NCT06508931","hint":"Recruiting"}},{"title":"r/r DLBCL 3L","progress":75,"inline":{"title":"NCT07288879","text":"A phase II, multi-center, single arm study to evaluate the safety and efficacy of zamtocabtagene autoleucel in subjects with relapsed/refractory diffuse large B cell lymphoma (DLBCL)<br/><br/>Please visit <a href=\'https://rctportal.mhlw.go.jp/detail/jr?trial_id=jRCT2033250384\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>rctportal.mhlw.go.jp (JRCT2033250384)</a>.","url":"https://clinicaltrials.gov/study/NCT07288879","hint":"Recruiting"}},{"title":"Lupus Nephritis, SLE, Systemic Sclerosis, Diffuse Cutaneous SSc","progress":50,"inline":{"title":"NCT06708845","text":"A phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT06708845\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT06708845)</a>.","url":"https://clinicaltrials.gov/study/NCT06708845","hint":"Recruiting"}},{"title":"Refractory Multiple Sclerosis","progress":75,"inline":{"title":"NCT07178431","text":"Please visit <a href=\'https://clinicaltrials.gov/study/NCT07178431\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>

1ClinicalTrials.gov (NCT07178431)</a>.","url":"https://clinicaltrials.gov/study/NCT07178431","hint":"Recruiting"}}]},{"title":"Zorpo&shy;cabta&shy;gene <nobr>autoleucel<sup>1</sup></nobr>","target":["CD19"],"indication":[{"title":"SLE, Systemic Sclerosis, Dermatomyositis, Polymyositis","progress":75,"inline":{"title":"NCT06347718","text":"A prospective, open-label, non-randomized, single-dose interventional basket study to assess the safety of anti-CD19 CAR-T cell therapy (zorpocabtagene autoleucel) in subjects with active B-driven autoimmune disease (SLE, SSc and DM/PM).<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT06347718\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT06347718)</a>.","url":"https://clinicaltrials.gov/study/NCT06347718","hint":"Recruiting"}},{"title":"Systemic lupus erythematosus (SLE)​","progress":50,"inline":{"title":"NCT06189157","text":"A phase l/ll open-label, multicentre, interventional single-arm trial of zorpocabtagene autoleucel in patients with refractory SLE systemic lupus erythematosus.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT06189157\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT06189157)</a>.","url":"https://clinicaltrials.gov/study/NCT06189157","hint":"Recruiting"}},{"title":"Recurrent Acute Lymphoblastic Leukemia, B-cell Lymphoma, Refractory B-cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia","progress":50,"inline":{"title":"NCT03853616","text":"A phase l/ll multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT03853616\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT03853616)</a>.","url":"https://clinicaltrials.gov/study/NCT03853616","hint":"Active"}}]},{"title":"MB-dNPM1-TCR.1","target":["dNPM1"],"indication":[{"title":"r/r Acute Myeloid Leukemia (AML)","progress":50,"inline":{"title":"NCT06424340","text":"A phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A*02:01 in patients with relapsed or refractory AML.<br/><br/>Please visit <a href=\'https://clinicaltrials.gov/study/NCT06424340\' target=\'_blank\' class=\'util-color-white\' rel=\'noopener noreferrer\'>ClinicalTrials.gov (NCT06424340)</a>.","url":"https://clinicaltrials.gov/study/NCT06424340","hint":"Recruiting"}}]},{"title":"Preclinical","target":[],"indication":[{"title":"Ovarian cancer, Glioblastoma, Pancreatic Cancer, Colorectal Cancer","progress":25}]}],"o":["Zamtocabtagene autoleucel and zorpocabtagene autoleucel are proposed International Nonproprietary Names (INN). The safety and efficacy of investigational agents have not been established. Programs details are subject to change."]}');var f=()=>a.createElement("div",{className:"pipeline"},a.createElement("div",{className:"container d-none d-lg-block mb-4"},a.createElement("div",{className:"row pipeline-headline"},a.createElement("div",{className:"col-12 col-lg-1-7"},"Program"),a.createElement("div",{className:"col-12 col-lg-2-7 text-left"},"Indication"),a.createElement("div",{className:"col-12 col-lg-1-7 text-center"},"Preclinical"),a.createElement("div",{className:"col-12 col-lg-1-7 text-center"},"Phase 1"),a.createElement("div",{className:"col-12 col-lg-1-7 text-center"},"Phase 2"),a.createElement("div",{className:"col-12 col-lg-1-7 text-center"},"Pivotal"))),h.T.map((e,t)=>a.createElement(g,{key:t,index:t,item:e})),a.createElement("div",{className:"container mt-4",id:"legend"},h.o.map((e,t)=>a.createElement("p",{key:t},a.createElement("sup",null,t+1)," ",e)),a.createElement("p",null,"*Part I complete; Part II recruiting"),a.createElement("p",null,a.createElement("strong",null,"CNSL"),", Central nervous system lymphoma; ",a.createElement("strong",null,"DLBCL"),", Diffuse large B-cell lymphoma; ",a.createElement("strong",null,"MCL"),", Mantle cell lymphoma; ",a.createElement("strong",null,"r/r"),", Relapsed/Refractory; ",a.createElement("strong",null,"SLE"),", Systemic lupus erythematosus; ",a.createElement("strong",null,"SSc"),", Systemic sclerosis")));var y=()=>

1a.createElement(n.A,{site:"clinicalprograms",footer:""},a.createElement(i.A,{title:"Clinical programs | Miltenyi Biomedicine GmbH",description:"Our oncology research focuses on tandem (dual-antigen) targeting strategies designed to address antigen escape in B-cell malignancies. Manufacturing relies on standardized, automated, closed processes that support GMP-compliant workflows. Beyond hematology, we are expanding our pipeline to explore additional indications, including solid tumors and autoimmune diseases, employing different cell therapy platforms."}),a.createElement(s.A,{className:"mb-3 stage--bg2 stage--clinicalprograms",site:"clinicalprograms"},a.createElement(r.A,{className:"d-lg-none",style:{width:"400px",bottom:"0%",left:"20%"},settings:{duration:"30000",translateX:"20px",translateY:"50px",rotate:"40deg"}},a.createElement("img",{src:l(283).A,alt:"Cell Mobile "})),a.createElement(r.A,{className:"d-none d-lg-block",style:{width:"600px",bottom:"30%",left:"-54%"},settings:{duration:"60000",translateX:"20px",translateY:"50px",rotate:"40deg"}},a.createElement("img",{src:l(283).A,alt:"Cell Left"})),a.createElement(r.A,{className:"d-none d-lg-block",style:{width:"500px",top:"-45%",right:"-10%"},settings:{duration:"40000",translateX:"-80px",translateY:"120px"}},a.createElement("img",{src:l(417).A,alt:"Cell Right"}))),a.createElement("div",{className:"container  mb-lg-5"},a.createElement("div",{className:"row "},a.createElement("div",{className:"col-12"},a.createElement("div",{className:"breadcrumb-wrapper -primary mt-5 mt-lg-0"},a.createElement(c.A,{class:"-primary",data:[{text:"Home",link:"/"},{text:"Cell therapy"},{text:"Clinical programs"}]}))),a.createElement("div",{className:"col-12 mt-3 "},a.createElement("h1",{className:"util-h1 util-color-primary"},"Clinical programs"),a.createElement("p",{className:"util-text-1 "},"Our oncology research focuses on tandem (dual-antigen) targeting strategies designed to address antigen escape in B-cell malignancies. Manufacturing relies on standardized, automated, closed processes that support GMP-compliant workflows. Beyond hematology, we are expanding our pipeline to explore additional indications, including solid tumors and autoimmune diseases, employing different cell therapy platforms.")))),a.createElement("div",{id:"pipeline",className:"container mt-lg-5 pt-5",style:{minHeight:"1000px"}},a.createElement("div",{className:"row"},a.createElement("div",{className:"col-12 col-lg-12 mb-5"},a.createElement("h2",{className:"util-h1 util-color-primary"},"Our pipeline"),a.createElement("p",{className:"util-text-1"},"Miltenyi has a diverse portfolio of proprietary product candidates for hematologic cancers, with several clinical trials currently underway or planned for the near future. The graphic shows examples of product candidates in late pre-clinical and clinical development stages. Additionally we are actively expanding our pipeline by applying our platforms to degenerative disorders, and solid tumors such as pancreatic cancer, ovarian cancer and glioblastoma.")),a.createElement("div",{className:"col-12"},a.createElement(f,null)))),a.createElement("div",{id:"pipeline",className:"container util-content-mb-2 "},a.createElement("div",{className:"row"},a.createElement("div",{className:"col-12 col-lg-12 text-lg-center mb-5"},a.createElement("a",{href:"https://clinicaltrials.gov/expert-search?term=AREA%5BLeadSponsorName%5D(Miltenyi%20Biomedicine)%20AND%20AREA%5BOverallStatus%5D(RECRUITING%20OR%20NOT_YET_RECRUITING%20OR%20ACTIVE_NOT_RECRUITING%20OR%20COMPLETED)",className:"btn btn--primary",target:"_blank",rel:"noopener noreferrer"},"View our clinical trials")))))},7712:function(e,t,l){var a=l(6540);t.A=e=>{const t=e.data.map(function(e){return e.link?a.createElement("li",{key:e.text},a.createElement("a",{href:e.link},e.text)):a.createElement("li",{key:e.text},e.text)});return a.createElement("ul",{className:"breadcrumb"+(e.class?" "+e.class:"")},t)}}}]);
2//# sourceMappingURL=component---src-pages-cell-therapy-clinical-programs-js-9772e7f9cf52900439d4.js.map